A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis
Tamanna Haque(Memorial Sloan Kettering Cancer Center), Michael R. Savona(Vanderbilt University), Alexander J. Silver(Brigham and Women's Hospital), Kelly L. Bolton(Washington University in St. Louis), Amit Verma(Albert Einstein College of Medicine), Aditi Shastri(The University of Texas MD Anderson Cancer Center), Abhay Singh(Cleveland Clinic), David Slosky(Jisc), Zhuoer Xie(Mayo Clinic), J. Brett Heimlich(Vanderbilt University Medical Center), Ashwin Kishtagari(Memorial Sloan Kettering Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Siddhartha Jaiswal(Stanford University), Danielle Hammond(The University of Texas MD Anderson Cancer Center), David P. Steensma(Harvard University), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Alexander G. Bick(Vanderbilt University), Yasmin Abaza(Northwestern University), Zoe King(Children's Hospital at Montefiore), Uma Borate(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 6
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
|Cell stem cell|2017|851
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
|Nature Genetics|2020|739